3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
3
Gastrointestinal
3
Thoracic
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Small Cell Lung Carcinoma
1
Sarcoma
1
Mesothelioma, Malignant
1
Colorectal Neoplasms
1
Anus Neoplasms
1
Interventions
Cyclophosphamide
9
Radiotherapy
8
Temozolomide
6
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Doxorubicin
6
pazopanib
5
Gemcitabine
5
pembrolizumab
4
Vincristine
4
Radiation
4
Etoposide
4
Docetaxel
4
Carboplatin
4
Biopsy
4
Trabectedin
3
Taxes
3
Specimen Handling
3
Paclitaxel
3
Nivolumab
3
Irinotecan
3
Drug Therapy
3
olaparib
2
niraparib
2
liposomal doxorubicin
2
fludarabine phosphate
2
fludarabine
2
brigimadlin
2
Trastuzumab
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
tislelizumab
×
Sarcoma
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn